|
FY2026
12 months to Mar 31, 2026
|
FY2025
12 months to Mar 31, 2025
|
FY2024
12 months to Mar 31, 2024
|
FY2023
12 months to Mar 31, 2023
|
FY2022
12 months to Mar 31, 2022
|
|
|---|---|---|---|---|---|
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation and amortization | |||||
| Depreciation | |||||
| Stock-based compensation | |||||
| Deferred income tax (benefit) expense | |||||
| Operating lease right-of-use asset | |||||
| Gain on sale of assets | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable, net | |||||
| Inventories, net | |||||
| Prepaid expenses and other current assets | |||||
| Deferred consideration, net of discount | |||||
| Accounts payable | |||||
| Accrued expenses and other current liabilities | |||||
| Withholding tax payable | |||||
| Operating lease liabilities | |||||
| Deferred revenue | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities: | |||||
| Purchases of property and equipment | |||||
| Deposits | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities: | |||||
| Proceeds from sale of stock, net | |||||
| Payments on PPP Loan | |||||
| Proceeds from exercise of employee stock options | |||||
| Payments for fractional shares related to reverse-split | |||||
| Principal payments on short-term debt | |||||
| Insurance premiums financed | |||||
| Net cash provided by financing activities | |||||
| Effect of exchange rate on cash and cash equivalents | |||||
| Net (decrease) increase in cash and cash equivalents | |||||
| Cash and cash equivalents, beginning of year | |||||
| Cash and cash equivalents, end of year | |||||
| Supplemental disclosure of cash flow information: | |||||
| Cash paid for interest | |||||
Loading...